

Applicants : BERMUDES, et al.
Application No. : Not Yet Known
Filing Date : Herewith
Page : 2

AMENDMENTS TO THE CLAIMS:

Please amend claims as follows:

Claim 1 (original): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.

Claim 2 (original): The composition according to claim 1 in which the bacterium is a Salmonella.

Claim 3 (original): The composition according to claim 1 in which the Gram-negative bacterium is Shigella.

Claim 4 (original): The composition according to claim 1 in which the gene product of interest is a proteinaceous molecule.

Claim 5 (original): The composition according to claim 1 in which the gene product of interest is an antigen.

Claim 6 (original): The composition according to claim 4 in which the molecule is selected from the group consisting a cytokine, a cytotoxin, a pro-drug converting enzyme and an anti-angiogenic agent.

Claim 7 (original): The composition according to claim 6 in which the cytotoxin is a bacteriocin.

Applicants : BERMUDES, et al.
Application No. : Not Yet Known
Filing Date : Herewith
Page : 3

Claim 8 (original): A kit comprising an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein, together with instructions for administering the attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage to a subject to deliver the gene product of interest.

Claim 9 (original): A kit comprising an attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage, wherein the genome of the bacteriophage has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein, together with instructions for administering the attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage to a subject to deliver the gene product of interest.

Claim 10 (canceled)

Claim 11 (original): A method for delivering an agent comprising administering, to a subject, a pharmaceutical composition comprising an attenuated Gram-negative bacterium containing a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the

Applicants : BERMUDES, et al.
Application No. : Not Yet Known
Filing Date : Herewith
Page : 4

genome of the bacteriophage has been modified to encode for a gene of interest as a fusion protein with a bacteriophage capsid protein.

Claim 12 (original): The method according to claim 11, in which the gene of interest is an antigen or a pro-drug converting enzyme.

Claim 13 (original): The method according to claim 11, in which the gene of interest is fused with a bacteriophage capsid protein.

Claim 14 (original): A method for delivering an agent comprising administering, to a subject, a pharmaceutical composition comprising an attenuated Gram-negative bacterium expressing the F' pilus and a filamentous bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode for a gene of interest as a fusion protein with a bacteriophage capsid protein.

Claim 15 (original): A method of inhibiting tumor growth or reducing tumor volume comprising administering, to a subject in need of such inhibition or reduction, a pharmaceutical composition comprising an attenuated, tumor-targeting Gram-negative bacterium containing a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.

Applicants : BERMUDES, et al.
Application No. : Not Yet Known
Filing Date : Herewith
Page : 5

Claim 16 (original): The method according to claim 15 in which the Gram-negative bacterium is *Salmonella* or *Shigella*.

Claim 17 (original): A method of inhibiting tumor growth or reducing tumor volume comprising administering, to a subject in need of such inhibition or reduction, a pharmaceutical composition comprising an attenuated, tumor-targeting Gram-negative bacterium expressing the F' pilus and a bacteriophage, wherein the bacteriophage genome has been modified to encode for a gene product of interest under the control of an eukaryotic promoter or wherein the genome of the bacteriophage has been modified to encode the gene of interest as a fusion protein with a bacteriophage capsid protein.

Claim 18 (original): The method according to claim 17 in which the Gram-negative bacterium is *Salmonella* or *Shigella*.

Claims 19-24 (canceled)